These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 17039648

  • 1. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S, Crowley J, Jones L, Young M, Sobell J.
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [Abstract] [Full Text] [Related]

  • 2. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ, Scherschun L.
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 4. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group.
    Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
    [Abstract] [Full Text] [Related]

  • 5. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group.
    JAMA; 2003 Dec 17; 290(23):3073-80. PubMed ID: 14679270
    [Abstract] [Full Text] [Related]

  • 6. Successful treatment of hand and foot psoriasis with infliximab.
    Di Lernia V, Guareschi E.
    Dermatol Online J; 2010 Jul 15; 16(7):8. PubMed ID: 20673536
    [Abstract] [Full Text] [Related]

  • 7. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis.
    Prossick TA, Belsito DV.
    Cutis; 2006 Sep 15; 78(3):178-80. PubMed ID: 17036660
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab.
    Mansouri B, Kivelevitch D, Campa M, Menter A.
    Clin Exp Dermatol; 2016 Apr 15; 41(3):324-6. PubMed ID: 26344848
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
    Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S.
    Dermatology; 2009 Apr 15; 218(2):146-50. PubMed ID: 18971577
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program.
    Foley P, Freeman M, Gebauer K, Murrell D, Shumack S, Tyson C, Varigos G.
    Int J Dermatol; 2009 Dec 15; 48(12):1376-84. PubMed ID: 19930495
    [Abstract] [Full Text] [Related]

  • 16. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 Dec 15; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efalizumab-associated papular psoriasis.
    Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N.
    Arch Dermatol; 2007 Jul 15; 143(7):900-6. PubMed ID: 17638735
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul 15; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.